The Role of Shed PrPc in the Neuropathogenesis of HIV Infection

Bezawit W. Megra, Eliseo A. Eugenin and Joan W. Berman
J Immunol July 1, 2017, 199 (1) 224-232; DOI: https://doi.org/10.4049/jimmunol.1601041

Abstract

HIV-1 enters the CNS soon after peripheral infection and causes chronic neuroinflammation and neuronal damage that leads to cognitive impairment in 40–70% of HIV-infected people. The nonpathogenic cellular isoform of the human prion protein (PrPc) is an adhesion molecule constitutively expressed in the CNS. Previously, our laboratory showed that shed PrPc (sPrPc) is increased in the cerebrospinal fluid of HIV-infected people with cognitive deficits as compared with infected people with no impairment. In this article, we demonstrate that CCL2 and TNF-α, inflammatory mediators that are elevated in the CNS of HIV-infected people, increase shedding of PrPc from human astrocytes by increasing the active form of the metalloprotease ADAM10. We show that the consequence of this shedding can be the production of inflammatory mediators, because treatment of astrocytes with rPrPc increased secretion of CCL2, CXCL-12, and IL-8. Supernatants from rPrPc-treated astrocytes containing factors produced in response to this treatment, but not rPrPc by itself, cause increased chemotaxis of both uninfected and HIV-infected human monocytes, suggesting a role for sPrPc in monocyte recruitment into the brain. Furthermore, we examined whether PrPc participates in glutamate uptake and found that rPrPc decreased uptake of this metabolite in astrocytes, which could lead to neurotoxicity and neuronal loss. Collectively, our data characterize mediators involved in PrPc shedding and the effect of this sPrPc on monocyte chemotaxis and glutamate uptake from astrocytes. We propose that shedding of PrPc could be a potential target for therapeutics to limit the cognitive impairment characteristic of neuroAIDS.

Introduction

Thirty-seven million people are living with HIV worldwide (1). Even with the success of combined antiretrovirals (cARTs), ∼40–70% of HIV-infected people develop a spectrum of cognitive and motor abnormalities that are collectively termed HIV-associated neurocognitive disorders (HANDs) (2–4). Because HIV-infected people are living longer, the prevalence of cognitive impairment is increasing and low-level chronic neuroinflammation and neuronal damage remain a significant public health issue (5).

HIV enters the CNS early after peripheral infection, predominantly through HIV-infected monocytes that cross the blood–brain barrier (BBB) (3, 6–8). After entering the CNS, these infected cells differentiate into perivascular macrophages and release virus that can infect macrophages, microglia, and to a lesser extent, astrocytes, as well as activate resident CNS cells (9–11). Activated and infected cells elaborate neuroinflammatory factors including CCL2/MCP-1 and TNF-α (12–14). CCL2, a potent monocyte chemoattractant, is elevated in the CNS and cerebrospinal fluid of individuals with HIV and remains elevated even with successful cART (15, 16). This can result in ongoing monocyte transmigration, reseeding of the CNS with virus, and chronic low-level inflammation and neuronal damage (17). TNF-α is produced predominantly by astrocytes and microglia, and can induce the production of cytokines and neurotoxic host factors, as well as activate HIV replication and cause the production of viral proteins (18–20). In addition, in neurons, this cytokine has been shown to cause apoptosis (21). Thus, TNF-α plays a key role in the progression of HIV CNS disease.

The cellular isoform of the human prion protein (PrPc) is the nonpathological isoform of the prion protein and is an adhesion molecule that is constitutively expressed by CNS cells including astrocytes, brain microvascular endothelial cells, neurons, as well as infiltrating leukocytes (22–25). PrPc is expressed on the cell membrane, where it is GPI anchored and can be cleaved and shed to the extracellular environment (26–28). In physiological conditions PrPc has been shown to be involved in leukocyte activation, monocyte transmigration, cell adhesion, macrophage phagocytosis, and glutamate uptake in murine astrocytes isolated from PrPc-deficient mice (29–32). However, its role in HIV neuropathogenesis is unknown.

Previously, our group demonstrated that HIV-seropositive people with HAND have higher amounts of shed PrPc (sPrPc) in their cerebrospinal fluid as compared with seropositive people with no impairment (33). In addition, in a pigtail SIV macaque model, sPrPc levels correlated with encephalitis (33). In these studies, cerebrospinal fluid sPrPc levels also correlated with cerebrospinal fluid CCL2, suggesting that this chemokine plays a role in the shedding of PrPc (33). Other groups have shown that a recombinant protein of human PrPc fused with the Fc portion of human IgG1 can activate signaling pathways including NF-κB, PI3K, and ERK in monocyte/macrophages (34). We therefore hypothesized that neuroinflammation during HIV infection of the CNS results in increased PrPc shedding, and that sPrPc participates in the development of HAND.

In this study, we demonstrate that CCL2 and TNF-α increase PrPc shedding from astrocytes. We examined astrocytes because they are the most abundant CNS cell type and have key functions in the brain including maintenance of neuronal function and survival (35, 36). To study the mechanism of this increased shedding, we examined the effect of these cytokines on the disintegrin metalloprotease ADAM10, a protease that had been shown to cleave PrPc in neurons. ADAM10 is a membrane-associated protein that can be found in two forms, active and inactive (37). The inactive form of ADAM10 has a propeptide covering its active site, preventing it from binding to its substrate. The active form of ADAM10, which is still cell membrane associated, has the proprotein cleaved and the metalloprotease domain freed to cleave proteins in close proximity to it in the plasma membrane, including N-cadherin, Notch, fractalkine, and amyloid precursor protein (38–42). We found that CCL2 and TNF-α increased PrPc shedding by inducing increased expression of the active form of ADAM10. We also showed that a specific ADAM10 inhibitor (GI254023X) decreased this CCL2- and TNF-α–mediated PrPc shedding to below baseline, demonstrating that this protease cleaves PrPc in astrocytes.

In addition, we determined that sPrPc contributes to neuroinflammation by mediating the production of CCL2, CXCL12, and IL-8 from astrocytes. We showed that supernatants of astrocytes treated with full-length human recombinant PrPc (rPrPc) that has the native conformation of PrPc, but not rPrPc by itself, cause increased chemotaxis of both uninfected and HIV-infected human primary monocytes above baseline. This suggests that factors produced from astrocytes in response to this protein are mediating chemotaxis and contribute to monocyte recruitment across the BBB and progression of HIV CNS pathogenesis. We also examined the role of rPrPc in another important astrocytic function, glutamate uptake. rPrPc decreased uptake of this metabolite in astrocytes, and this could lead to neurotoxicity and neuronal loss. Thus, we have shown that sPrPc is involved in the processes of HIV neuropathogenesis and contributes to inflammation and neuronal damage.

Materials and Methods

Primary human astrocyte cultures

Primary human astrocytes were obtained as part of a research protocol at the Albert Einstein College of Medicine and were cultured as previously described (43). To obtain pure astrocytes, we plated mixed cultures of neurons and astrocytes at a density of 4.5 × 107 in DMEM supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 1% nonessential amino acids (all from Thermo Fisher Scientific, Waltham, MA), and 2% HEPES (USB, Cleveland, OH). After 1 wk in culture, cells were dissociated and replated to eliminate microglia and neurons. After this, all cells are GFAP+.

CCL2, TNF-α, and ADAM10 inhibitor (GI254023X) treatment

Primary human astrocytes were cultured in 60-mm plates at a starting density of 300,000 cells for 4–5 d before treatments. Human recombinant CCL2 (PeproTech, Rocky Hill, NJ) was added to astrocytes in serum-free media to a final concentration of 200 ng/ml. Human recombinant TNF-α (PeproTech) was added to cells in serum-free astrocyte media at a concentration of 10 ng/ml. Control cultures were treated with ddH2O, the CCL2 and TNF-α diluent. To examine whether CCL2 and TNF-α have synergistic or additive effects, we added CCL2 (200 ng/ml) and TNF-α (10 ng/ml) concomitantly to astrocyte cultures for some experiments. For experiments with the ADAM10 inhibitor (GI254023X; courtesy of Dr. Schmidt Technische Universität Darmstadt, Darmstadt, Germany) (44), astrocytes were treated with GI254023X (5 μM) concomitantly with CCL2 (200 ng/ml) or TNF-α (10 ng/ml).

rPrPc treatment

Astrocytes were cultured in DMEM with 10% FBS on 96-well tissue culture plates at 10,000 cells per well for 2–3 d. Full-length human rPrPc (Jena Bioscience, Jena, Germany) was added to fresh serum-free DMEM media to a final concentration of 10 μg/ml. Media were aspirated from wells, and 50 μl of rPrPc-supplemented media was added to each well. Negative control cells received serum-free DMEM with an equal concentration of the diluent, NaAc. Positive control cells were treated with 10 ng/ml IL-1β to verify the astrocyte response to stimulation. After 24 h, media were collected from each well and analyzed by ELISA.

Primary monocyte isolation and culture

Leukopaks were obtained from the New York Blood Center, and PBMCs were isolated using Ficoll-Paque (GE Healthcare, Uppsala, Sweden). Monocytes were isolated from PBMCs using EasySep Human CD14 Positive Selection Kit according to the manufacturer’s instructions (STEMCELL Technologies, Vancouver, BC, Canada). CD14+ monocytes were cultured nonadherently in Teflon-coated flasks at a density of 2 × 106 cells/ml in RPMI 1640 media (Thermo Fisher Scientific) supplemented with 10% heat-inactivated human serum type AB and 5% heat-inactivated FBS (Lonza, Walkersville, MD), 1% HEPES, 1% penicillin/streptomycin, and 10 ng/ml M-CSF (PeproTech) as previously described (45). This culture system yields 70% mature CD14+ CD16+ monocytes (45).

HIV infection of mature monocytes

After 3 d of nonadherent culture, monocytes were infected with the R5 tropic isolate HIV-1ADA (National Institutes of Health Repository, Germantown, MD) as previously reported (33). In brief, cells were pelleted and resuspended at a density of 2 × 106 cells/ml in monocyte media. Monocytes were then infected with 20 ng/ml HIV-1ADA. After 24 h, cells were pelleted, washed, and fresh media were added. On the third day postinfection, supernatants were collected and viral replication was assessed by HIV-p24 AlphaLISA according to manufacturer’s instructions (Advanced BioScience Laboratories, Kensington, MD).

Chemokine ELISAs

To assay for cytokines released from astrocytes, we treated cells with full-length human rPrPc for 24 h, and collected and centrifuged media at 3000 rpm for 5 min at 4°C to remove cellular debris, and assayed for CCL2/MCP-1, CXCL12/SDF-1, and IL-8 using DuoSet ELISA Kits according to the manufacturer’s instructions (all from R&D Systems, Minneapolis, MN). Limits of detection of these kits are 9.38 pg/ml for CCL2 and 31.25 pg/ml for both CXCL12 and IL-8.

Western blotting

To determine whether CCL2 and TNF-α induced PrPc shedding, media were collected from both control and treatment plates and cell debris was removed by centrifuging at 3000 rpm 4°C for 5 min. After centrifugation, supernatants were concentrated to 250 μl using an Amicon Ultra-15, 10-kDa centrifugal filter device (Millipore, Bellerica, MA). Equal volumes of supernatants were loaded onto 4–20% polyacrylamide gels, separated by electrophoresis, and transferred to nitrocellulose membranes (GE Healthcare Life Sciences). Membranes were blocked for 2 h at room temperature with 5% nonfat dry milk and 3% BSA in TBST. Blots were probed with Ab against the extracellular portion of PrPc (SAF 32 clone, 1:200 dilution; Cayman Chemical, Ann Arbor, MI) overnight at 4°C, washed with TBST, and probed with anti-mouse IgG-HRP secondary Ab (1:2000 dilution; Cell Signaling, Boston, MA) for 1 h at room temperature. Signal was detected using Western Lightning Plus-ECL (Perkin Elmer, Waltham, MA). To assay for active ADAM10, we treated astrocytes with CCL2 or TNF-α, and cells were lysed with cell lysis buffer (Cell Signaling) supplemented with protease inhibitor mixture (Roche, Indianapolis, MN). After removing debris by centrifugation, we determined total cellular protein concentration by Bio-Rad protein assay (Bio-Rad, Hercules, CA). Cell lysates were loaded onto 4–20% polyacrylamide gels, separated by electrophoresis, and transferred to nitrocellulose membranes. Membranes were blocked for 2 h at room temperature with 5% nonfat dry milk and 3% BSA in TBST, and blots were probed with Ab against ADAM10 (1:200 dilution; Santa Cruz, Dallas, TX) overnight at 4°C, washed with TBST, and probed with anti-rabbit IgG-HRP secondary Ab (1:2000 dilution; Cell signaling) for 1 h at room temperature. The ADAM10 Ab detects both the pro and active forms of ADAM10. Signal was detected using Western Lightning Plus-ECL. Blots were stripped using Restore Plus Western blot Stripping Buffer (Thermo Scientific), and reprobed with Ab against GAPDH (1:500 dilution; Cell Signaling), for 1 h at room temperature, washed with TBST, and probed with anti-mouse IgG-HRP secondary Ab (1:2000 dilution; Cell Signaling) for 1 h at room temperature. Data were quantified by densitometry using UN-SCAN-IT software (Silk Scientific).

Chemotaxis assay

Chemotaxis assays were performed with a Neuro Probe 48-well Micro Chemotaxis Chamber (Neuro Probe, Gaithersburg, MD) as previously described (46). Astrocytes were treated with rPrPc (10 μg/ml) or its diluent NaAc. Supernatants were collected, spun, and placed in wells in the bottom chamber of the apparatus. A polycarbonate filter containing 5-μm pores was placed between the bottom and top chambers. Uninfected or HIV-infected mature monocytes (2.5 × 105) in RPMI 1640 with 2% FBS were added to the wells in the top chamber and allowed to migrate for 1 h at 37°C. The membrane was then removed and the cells that had migrated through the membrane and bound to its underside were fixed and stained with the Diff-Quik Stain Set (Siemens, Munich, Germany). Chemotaxis was quantified by densitometry using UN-SCAN-IT software.

Glutamate uptake assay

For glutamate uptake studies, astrocytes were cultured at 3 × 104 cells per well on 24-well plates until they were confluent (2–3 d). Media for cells were changed to glutamine-free DMEM (Thermo Fisher Scientific) the day before the experiment. Astrocytes were treated with rPrPc for 10 min after which [3H]l-glutamate (0.5 μCi/ml) (Moravek Biochemicals, Brea, CA) and 50 μM unlabeled glutamate (Sigma-Aldrich, Allentown, PA) were added to cells with rPrPc still present. Cells were incubated for an additional 1 h. Glutamate uptake was stopped by addition of ice-cold solution of Kreps-HEPES buffer (140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 15 mM HEPES, and 1.2 mM MgSO4). After three consecutive washes, cells were lysed with NCS tissue solubilizing agent (MP Biomedicals, Boston, MA), and lysate was collected for scintillation counting. cpm were determined for 3 min.

Results

CCL2 and TNF-α cause increased shedding of PrPc from astrocytes

Astrocytes are the most abundant cell type in the CNS with many specialized functions, and they play a prominent role in HIV CNS disease (10, 35, 47). They express and shed PrPc at baseline levels in vitro at a concentration of ∼128 ng/ml per 105 cells (33, 48). Our laboratory HIV-positive individuals with cognitive impairment have increased sPrPc in their cerebrospinal fluid that correlates with cerebrospinal fluid CCL2, suggesting a dysregulation in the shedding of this protein by CCL2 (33). TNF-α is released by activated microglia and astrocytes during HIV infection of the CNS and has been shown to be increased in the cerebrospinal fluid of HIV-infected people with dementia (49). To determine the effect of CCL2 and TNF-α on PrPc shedding, we treated astrocytes with CCL2 (200 ng/ml) and TNF-α (10 ng/ml), and supernatants were collected and analyzed for sPrPc by Western blot. After treatments, cell viability of cultures was evaluated by trypan blue staining, and cultures were found to be free of dead or dying cells. CCL2 and TNF-α increased PrPc shedding (37 kDa) after 24 h of treatment (Fig. 1). These experiments were performed four independent times with similar findings in which CCL2 increased PrPc shedding 1.7-fold above baseline and TNF-α increased PrPc shedding 2.0-fold above baseline (quantification shown in Figs. 2 and 3). We also determined whether concomitant treatment with CCL2 and TNF-α resulted in a further increase in sPrPc. In these experiments we found that CCL2 increased PrPc shedding by 2.06-fold above baseline and TNF-α increased shedding by 1.933-fold. Concomitant treatment of cells with CCL2 and TNF-α resulted in a 2.27-fold increase, n = 3 (data not shown). These results were not statistically different from data obtained with individual cytokine treatments and show that the effect of CCL2 and TNF-α is neither synergic nor additive. These results suggest that astrocytes are a major source of increased sPrPc in the cerebrospinal fluid of HIV-positive individuals, and that CCL2 and TNF-α may play an important role in CNS PrPc shedding.

FIGURE 1.
FIGURE 1.

CCL2 and TNF-α induce significant PrPc shedding above baseline. Astrocytes were treated with 200 ng/ml CCL2 or 10 ng/ml TNF-α for 24 h. Supernatants were collected, concentrated, and electrophoresed, and Western blotting was performed. Representative blot of n = 4; quantification is in Fig. 3.

FIGURE 2.
FIGURE 2.

CCL2 and TNF-α increase active ADAM10. (A) Schematic representation of PrPc attached to the cell membrane by a GPI anchor. We hypothesize that shedding of PrPc into the extracellular environment is mediated by the active form of the cell-associated protease ADAM10. (B) Astrocyte cultures were treated with CCL2 (200 ng/ml) or TNF-α (10 ng/ml) for either 2 or 4 h, and lysates were prepared to examine active ADAM10 by Western blotting. GAPDH was used as a loading control. (C) Four independent experiments were quantified at the time point with the maximal change. CCL2 increased active ADAM10 by 1.5-fold at 2 and 4 h. TNF-α did not increase active ADAM10 at these time points. (D) Astrocyte cultures were treated with TNF-α (10 ng/ml) for 6, 8, or 12 h, and lysates were prepared to examine active ADAM10 by Western blotting. GAPDH was the loading control. (E) Four independent experiments were quantified at the time point with the maximal change. TNF-α increased active ADAM10 at 6, 8, or 12 h by 1.5-fold. Significance was determined using a two-tailed paired Student t test. *p < 0.05, **p < 0.01.

FIGURE 3.
FIGURE 3.

CCL2 and TNF-α induce increased PrPc shedding that is inhibited by the ADAM10 inhibitor, GI254023X. (A) Astrocytes were treated with CCL2 (200 ng/ml), TNF-α (10 ng/ml), CCl2 with GI254023X (5 μM), or TNF-α with GI254023× (5 μM) for 24 h. Supernatants were collected, concentrated, and analyzed by Western blotting. Four independent experiments were quantified by densitometry. (B) CCL2 and (C) TNF-α increased PrPc shedding by 1.7-fold and 2.0-fold, respectively. This increased shedding was reduced to or below baseline levels by cotreatment of CCL2 or TNF-α with GI254023X. Western blot image was cut (where it is indicated with white vertical line) to remove wells that contained samples that are irrelevant for this figure. Four independent experiments were quantified, and significance was determined using a two-tailed paired Student t test. *p < 0.05.

CCL2 and TNF-α increase active ADAM10

In neurons, it was shown that the cell-associated active disintegrin metalloprotease (ADAM10) cleaves PrPc from the cell membrane, but PrPc shedding from human astrocytes had not been studied extensively (50). To examine a mechanism by which CCL2 and TNF-α increase PrPc shedding, we studied whether these cytokines activate ADAM10 in astrocytes. Because both the active and inactive forms of ADAM10 are cell-associated protease, astrocytes were grown to confluency and treated with CCL2 or TNF-α, and cell lysate was prepared and analyzed by Western blotting. Results demonstrate that astrocytes express both the pro and active forms of ADAM10, and that CCL2 and TNF-α increase the active form. Densitometry was performed in which active ADAM10 was compared with a loading control, GAPDH, and these values were compared between control and CCL2-treated cells and control and TNF-α–treated cells. Quantification was performed at the time point with the maximal change. Results are reported as fold change relative to control. In four independent experiments, CCL2 increased active ADAM10, at either 2 or 4 h by 1.5-fold (Fig. 2B), and TNF-α increased ADAM10 at later time points, 6, 8, or 12 h by 1.5-fold (Fig. 2C).

CCL2- and TNF-α–induced PrPc shedding in astrocytes is mediated by active ADAM10

We found that CCL2 and TNF-α increased PrPc shedding and also induced increased expression of the active form of ADAM10, suggesting a mechanism for the increased PrPc shedding caused by these factors. Therefore, we used a specific ADAM10 inhibitor (GI254023X), a small-molecule inhibitor that has been shown to inhibit ADAM10 100-fold more effectively than it affects ADAM17, to examine whether it will block this cytokine-mediated increased shedding (44). Astrocytes were treated with GI254023X concomitantly with CCL2 and TNF-α. Western blot analyses of supernatants from treated cells demonstrate that astrocytes shed PrPc at baseline levels, and that CCL2 and TNF-α increase this shedding (Fig. 3A). Densitometric quantification of four independent experiments shows that CCL2 increased PrPc shedding at 24 h by 1.7-fold, and the ADAM10 inhibitor brought this down to below baseline (Fig. 3B). Similarly, TNF-α increased PrPc shedding at 24 h by 2-fold, and this increase was again brought below baseline by the inhibitor (Fig. 3C). These results demonstrate that ADAM10 cleaves PrPc in astrocytes, and that the increased shedding mediated by CCL2 and TNF-α is by active ADAM10.

rPrPc increases the production of inflammatory factors by astrocytes

To examine the effect of sPrPc on cytokine production, and therefore its contribution to CNS damage, we treated human primary astrocytes with rPrPc (10 μg/ml). This concentration is within the range for 24 h of what is found in the cerebrospinal fluid of HIV-seropositive individuals with cognitive impairment (33). In a different study, this concentration of PrPc was also found to induce the production of inflammatory factors and activate NF-κB and ERK signaling pathways in human macrophages (34). Soluble inflammatory mediators, CCL2, CXCL12, and IL-8, were quantified by ELISA. CCL2 and CXCL12 are chemokines that are important in recruitment of monocytes across the BBB, which is the first step in viral seeding of the CNS and subsequent establishment of HANDs. They are also increased in the cerebrospinal fluid of HIV-infected individuals even on cART (51). In addition, IL-8 increases monocyte adhesion to endothelial cells, contributing to the migration of monocytes across the BBB (52). At baseline conditions, astrocytes cultured in 96-well plates secreted 21,876 pg/ml CCL2, which increased to 42,653 pg/ml (1.9-fold) in response to rPrPc treatment. CXCL12 secretion increased from 343 to 549 pg/ml (1.6-fold) and IL-8 secretion increased from 39 to 60 pg/ml (1.5-fold) in response to rPrPc (Fig. 4). This suggests that sPrPc alters astrocyte function and may play an important role in HIV-1 neuropathogenesis by increasing inflammatory factors within the CNS.

FIGURE 4.
FIGURE 4.

rPrPc increases the production of inflammatory mediators by astrocytes. Astrocytes were treated with 10 μg/ml recombinant human full-length PrPc for 24 h followed by collection of media and quantification of factors by ELISA. Astrocytes secreted increased (A) CCL2 from 21,876 to 42,652 pg/ml, (B) CXCL12 from 343 to 549 pg/ml, and (C) IL-8 from 39 to 60 pg/ml in response to rPrPc. n = 9, 7, and 6 independent experiments, respectively. Significance was determined using a two-tailed paired Student t test. *p < 0.05, **p < 0.01, ***p < 0.005.

Supernatants of astrocytes treated with rcPrPc mediate increased chemotaxis of uninfected and HIV-infected monocytes

Astrocytes release cytokines in response to rPrPc treatment. To test the effect of these inflammatory factors on monocyte recruitment, we treated astrocytes with 10 μg/ml rPrPc or its diluent NaAc for 24 h. Supernatants from both control and rPrPc-treated astrocytes were collected and applied to the lower part of a chemotaxis chamber. A total of 250,000 uninfected or HIV-1ADA–infected primary human monocytes from our culture system (see Materials and Methods) in RPMI 1640 supplemented with 2% FBS were added to the top wells and allowed to chemotax for 1 h at 37°C across a polycarbonate filter with 5-μm pores that separated the upper and lower chambers. The membrane was removed, and cells that had migrated through the membrane and bound to its underside were fixed and stained with the Diff-Quik Stain Set. Chemotaxis was quantified by densitometry. Both uninfected and HIV-infected monocytes exhibited baseline chemotaxis to supernatants collected from diluent-treated astrocyte because of the low level production of chemokines by astrocytes under baseline conditions. Supernatants from astrocytes treated with rPrPc mediated significant increases in chemotaxis of both uninfected and HIV-infected monocytes above baseline by 1.3- and 1.4-fold, respectively (Fig. 5). To determine whether rPrPc is chemotactic by itself, media supplemented with 10 μg/ml rPrPc was added to the lower part of the chemotaxis chamber and monocytes to the top chamber and allowed to chemotax for 1 h. Media supplemented with rPrPc did not cause chemotaxis of either uninfected or infected monocytes by itself (results not shown), indicating that supernatants from rPrPc-treated astrocytes contain factors produced in response to the rPrPc treatment that mediate monocyte chemotaxis. These results indicate that sPrPc may contribute to monocyte recruitment, viral seeding of the CNS, and inflammation in HIV neuropathogenesis.

FIGURE 5.
FIGURE 5.

Supernatants from astrocytes treated with rPrPc mediate increased chemotaxis of uninfected and HIV-infected human monocytes. Astrocytes were treated with rPrPc (10 μg/ml) for 24 h. Supernatants were collected and applied to the lower chamber of a chemotaxis apparatus. Uninfected and HIV-infected monocytes (2.5 × 105) were applied to the upper chamber and allowed to chemotax for 1 h. The filter separating the chambers was removed, fixed, and stained using Diff-Quik Stain Set. The total number of migrated cells per well was quantified by densitometry. Supernatants from rPrPc-treated astrocytes mediated increased chemotaxis of both uninfected and HIV-infected monocytes by 1.3- and 1.4-fold, respectively. n = 5 independent experiments. Media containing rPrPc did not cause chemotaxis (data not shown). Significance was determined using a two-tailed paired Student t test. *p < 0.05.

rPrPc decreases glutamate uptake

Astrocytes are essential for maintaining neuronal health by regulating extracellular concentrations of ions and metabolites, including glutamate (53). Insufficient glutamate uptake by astrocytes leads to neurotoxicity and death (54). In mouse astrocytes, cell surface PrPc was shown to facilitate glutamate uptake by increasing the binding of glutamate to its transporters (32). In different studies, surface PrPc was shown to bind to itself, forming homotypic interactions (29, 55). Therefore, we hypothesized that increased sPrPc will bind to cell-associated PrPc on astrocytes, inhibiting the ability of surface PrPc to facilitate glutamate uptake. To test this hypothesis, we grew human astrocytes in 24-well plates (30,000 cells per well) and placed them in serum-free and glutamine-free media 24 h before the study. Human astrocytes were pretreated with rPrPc (10 μg/ml) for 10 min; then 0.5 μCi/ml [3H]l-glutamate and 50 μM unlabeled glutamate were added for 1 h. [3H]glutamate uptake was quantified and compared between control and rPrPc-treated groups. We found that glutamate uptake was significantly decreased in astrocytes treated with rPrPc by 0.4-fold (Fig. 6). These results indicate that increased sPrPc in the CNS may lead to neurotoxicity and neuronal loss by impairing glutamate uptake by astrocytes.

FIGURE 6.
FIGURE 6.

rPrPc treatment of human astrocytes results in decreased glutamate uptake. Astrocytes were grown to confluence and placed in glutamine-free, serum-free media 24 h before study. Cells were pretreated with rPrPc(10 μg/ml) for 10 min and then treated with [3H]l-glutamate (0.5 μCi/ml) and unlabeled glutamate (50 μM) in the continued presence of rPrPc for 1 h. Astrocytes treated with rPrPc exhibited a significant decrease in glutamate uptake by 0.4-fold below baseline. n = 5 independent experiments. Significance was determined using a two-tailed paired Student t test. **p < 0.01.

Discussion

PrPc is a GPI-anchored protein found in lipid rafts of the cell membrane and is expressed on cells of the CNS. Our laboratory previously showed that sPrPc is highly increased in the cerebrospinal fluid of neurocognitively impaired HIV-1–infected individuals, but not in HIV-infected individuals with normal cognitive function. In this study, we show that the cytokines CCL2 and TNF-α increase the shedding of PrPc from astrocytes by inducing the activation of the metalloproteinase ADAM10. Although ADAM10 had previously been reported to be the sheddase for PrPc for some cell types including murine neuronal cells, immortalized neuronal cells, and transfected HEK cells, to our knowledge, this is the first study to show that ADAM10 is the protease that cleaves PrPc from human astrocytes. We showed that CCL2 and TNF-α increase expression of active ADAM10. In HEK293 cells, proprotein convertases (PC)7 and furin were shown to cleave the ADAM10 propeptide, resulting in increased expression of active ADAM10 (56).

We hypothesized that CCL2 and TNF-α increase active ADAM10 by activating PC7 and furin. Therefore, we examined whether these cytokines activate ADAM10 through a PC7- and furin-mediated mechanism. These convertases have been shown to be regulated through Notch1 signaling (57). The Notch protein has extracellular, transmembrane (TM), and intracellular domains (58). During activation, the Notch protein extracellular domain is cleaved from the TM domain and Notch intracellular domain (NICD) (58). After that cleavage, the TM domain is separated from NICD by γ-secretase, allowing the NICD to translocate to the nucleus, where it activates various transcription factors including Hey1 and Hes1 (59–62). TNF-α has been shown to activate Notch signaling and increase the gene expression of transcription factors Hey and Hes1 in fibroblasts, nucleus pulposus cells, and melanoma cell lines (57, 62–64). We studied whether CCL2 and TNF-α activated ADAM0 by increasing activation of PC7 and furin through Notch1-mediated signaling by measuring the gene expression of Hes1 and Hey1. We found that these cytokines decreased both Hes1 and Hey1 at various time points (data not shown). This suggests that TNF-α and CCL2 do not activate ADAM10 through PC7 and furin. A possible mechanism by which CCL2 and TNF-α are regulating ADAM10 activation may be through other PCs. Seven PCs have been identified: furin, PC1 (also known as PC1/3), PC2, PACE4, PC4, PC5/PC6, and PC7. Studies have shown that, in addition to furin, proprotein convertases, including PC1, PC2, PACE-4, and PC5/PC6, result in cleavage and activation of ADAM17, which is a close relative of ADAM10 (65). Therefore, further studies will address whether CCL2 and TNF-α result in activation of ADAM10 by affecting these PCs.

Another mechanism by which ADAM10 can be processed is through ADAM9. Studies have shown that ADAM9 is involved in the ectodomain shedding of ADAM10. After it is released from the ectodomain, some studies demonstrate that the activity of ADAM10 is diminished, whereas others show that it is actually increased, possibly because it is not restricted to the cell membrane and to cell membrane proteins surrounding it (66, 67). However, because the type of activation that is induced in astrocytes by CCL2 and TNF-α is maturation of ADAM10, it is unlikely that ADAM9 is involved in this process.

Although sPrPc is found in human cerebrospinal fluid and serum, the specific functions of this protein have not been addressed extensively in the context of HIV CNS pathogenesis (33, 68). In this study, we examined the effect of sPrPc on astrocyte cytokine production and glutamate uptake, functions dysregulated during HIV infection of the CNS. We found sPrPc is an important mediator of the astrocyte inflammatory response by increasing CCL2, CXC12, and IL-8. Our studies suggest that PrPc shedding in the CNS is self-amplifying, in that rPrPc treatment of astrocytes increases the production of CCL2, and CCL2 increases the shedding of PrPc from astrocytes. This is consistent with our previous finding that increased cerebrospinal fluid CCL2 and sPrPc levels are correlative in HIV+ individuals with cognitive impairment (33). Both cell-associated PrPc and sPrPc are neurotrophins and have been associated with neuroprotection from toxic insult and maintenance of synaptic plasticity (69). Therefore, increased PrPc shedding may be an initial protective response to neuronal injury in HIV-seropositive people with neurocognitive impairment. However, although increased sPrPc might be initially protective, it is likely that it will contribute to CNS injury by inducing production of cytokines that mediate monocyte recruitment and viral seeding of the CNS, and by causing decreased glutamate uptake.

Some mechanisms of the effects of rPrPc on monocyte/macrophages have been examined previously. In one study, rPrPc bound to the surface of monocytes/macrophages and activated ERK and NF-κB pathways, resulting in TNF-α, IL-1β, and IL-6 production (34). In that study monocytes were treated with rPrPc that had the Fc portion of the human IgG1 as a fusion protein, and it was shown by flow cytometry that rPrPc bound to the surface of monocytes. In another study, recombinant murine PrPc treatment of monocyte/macrophages was shown to activate the Src-like kinases, as well as Syk and Pyk2 (70). Although we and other groups have shown that rPrPc induces the release of cytokines from cells, a possible binding partner for sPrPc has not been identified. In neurons, PrPc has been shown to bind to neural cell adhesion molecule and to the laminin receptor precursor protein (70, 71). Another possible interaction, and what we hypothesize is taking place in our study, is a homotypic interaction between soluble PrPc and membrane PrPc.

Astrocytes are essential in maintaining CNS homeostasis and regulating extracellular metabolite concentration including glutamate (72). Accumulation of high concentrations of glutamate results in neurotoxicity and neuronal degeneration. Because astrocytes are the principle means of clearing glutamate from the neuronal environment, factors that might inhibit or facilitate this glutamate uptake need to be characterized. Astrocytes from PrPc knockout mice were shown to exhibit decreased glutamate uptake (32). Kinetic experiments from this study indicated that the difference in glutamate uptake in PrPc-deficient mice is the result of glutamate affinity to its transporter, and that cell-associated PrPc facilitates uptake of this neurotransmitter (32). Furthermore, treatment of wild type mice with the cellular prion protein–derived peptide PrP106-126 inhibited glutamate uptake. This effect was specific for wild type astrocytes, because astrocytes from PrPc knockout mice were not affected by this treatment, suggesting that PrP106-126 interacts with cell-associated PrPc and blocks its function. However, the use of PrP106-125 peptide as a model of cellular prion protein is controversial because this peptide forms toxic aggregates displaying properties of prion protein scrapie (73, 74). In our study, we found that pretreatment of astrocytes with full-length human rPrPc caused decreased glutamate uptake. We propose that increased sPrPc binds to cell-associated PrPc on astrocytes, limiting the cell-associated protein’s ability to facilitate glutamate uptake. Binding studies to address this hypothesis will be performed in future experiments.

PrPc in other CNS pathologies including Alzheimer disease (AD) has been studied (75–78). CNS PrPc is increased in people with AD and regionally localized with amyloid-β (Aβ) plaques (79, 80). Cell-associated PrPc is hypothesized to play a role in the progression of AD by acting as a receptor of Aβ–oligomers through which oligomers mediate their neurotoxic effect (76). Alternatively, the GPI anchor free rPrPc was shown to prevent fibrillization and toxic oligomer formation, potentially by binding and sequestering Aβ oligomers and preventing them from plaque formation (81). Similar to our study in which cell-associated PrPc and sPrPc have different roles in HIV CNS pathogenesis, these findings suggest that cell surface anchored PrPc may be injurious and sPrPc may be protective during AD neuropathogenesis. In contrast with these studies, our findings suggest that sPrPc plays an inflammatory and neurotoxic role during HIV CNS infection. Levels of sPrPc in the cerebrospinal fluid have been examined in other CNS diseases including Lewy body dementia, Parkinson’s disease, multiple sclerosis, and cerebral ischemia (82). However, the role of sPrPc in the development or progression of these diseases has not yet been examined.

Our data suggest that neuroinflammation during HIV CNS infection results in increased shedding of PrPc from astrocytes by inducing active ADAM10. This increased sPrPc, in addition to contributing to increased monocyte recruitment into the CNS by increasing the production of cytokines from astrocytes, may lead to neurotoxicity and neuronal loss by inhibiting glutamate uptake in astrocytes. Therefore, targeting PrPc shedding may be a therapeutic approach to limit HIV neuropathogenesis.

In addition to cleaving PrPc and contributing to neuroinflammation during HIV infection of the CNS, ADAM10 has been reported to be involved in dysregulated shedding that is associated with cardiovascular diseases, neurodegeneration, and cancer (83–85). Therefore, ADAM10 has increasingly become a target for therapy. Until recently, clinical trials inhibiting ADAM10 used broad-spectrum metalloprotease inhibitors and have failed because of toxicity resulting from nonselectivity and low bioavailability (86). However, the next generation of long-acting and highly selective inhibitors are now being developed (87). These might serve as appropriate therapy to prevent the shedding of PrPc and reduce neuroinflammation caused by HIV infection of the CNS.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Dr. Boris Schmidt at Technische Universität Darmstadt, Germany, for providing the ADAM10 inhibitor, GI254023X. We also thank Dr. Tina Calderon, Dr. Loreto-Torres Carvallo, Dr. Peter J. Gaskill, Dr. Dionna Williams, Matias Jaureguiberry, Lillie Lopez, Mike Veenstra, and Courtney Veilleux for valuable contributions to this project.

Footnotes

  • This work was supported by National Institutes of Health Grants R01MH075679 (to J.W.B.), R21MH102113-01A1 (to J.W.B.), R01MH090958 (to J.W.B. and B.W.M.), R01MH07754208 (to J.W.B. and B.W.M.), and MH096625 (to E.A.E.) and Public Health Research Institute funding (to E.A.E.).

  • Abbreviations used in this article:

    Aβ
    amyloid-β
    AD
    Alzheimer disease
    BBB
    blood–brain barrier
    cART
    combined antiretroviral
    HAND
    HIV-associated neurocognitive disorder
    NICD
    Notch intracellular domain
    PC
    proprotein convertase
    PrPc
    cellular isoform of the human prion protein
    rPrPc
    recombinant PrPc
    sPrPc
    shed PrPc
    TM
    transmembrane.

  • Received June 15, 2016.
  • Accepted April 21, 2017.

References

  1. ↵
    1. UNAIDS
    . 2016. Global AIDs Update 2016. Available at: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016. Accessed: May 7, 2016.
  2. ↵
    1. Heaton, R. K.,
    2. D. R. Franklin,
    3. R. J. Ellis,
    4. J. A. McCutchan,
    5. S. L. Letendre,
    6. S. Leblanc,
    7. S. H. Corkran,
    8. N. A. Duarte,
    9. D. B. Clifford,
    10. S. P. Woods, et al, CHARTER Group, HNRC Group
    . 2011. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17: 3–16.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ances, B. M.,
    2. R. J. Ellis
    . 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27: 86–92.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kaul, M.,
    2. J. Zheng,
    3. S. Okamoto,
    4. H. E. Gendelman,
    5. S. A. Lipton
    . 2005. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 12(Suppl. 1): 878–892.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Valcour, V.,
    2. T. Chalermchai,
    3. N. Sailasuta,
    4. M. Marovich,
    5. S. Lerdlum,
    6. D. Suttichom,
    7. N. C. Suwanwela,
    8. L. Jagodzinski,
    9. N. Michael,
    10. S. Spudich, et al, RV254/SEARCH 010 Study Group
    . 2012. Central nervous system viral invasion and inflammation during acute HIV infection. J. Infect. Dis. 206: 275–282.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Davis, L. E.,
    2. B. L. Hjelle,
    3. V. E. Miller,
    4. D. L. Palmer,
    5. A. L. Llewellyn,
    6. T. L. Merlin,
    7. S. A. Young,
    8. R. G. Mills,
    9. W. Wachsman,
    10. C. A. Wiley
    . 1992. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736–1739.
    OpenUrlCrossRefPubMed
    1. Wiley, C. A.,
    2. R. D. Schrier,
    3. J. A. Nelson,
    4. P. W. Lampert,
    5. M. B. Oldstone
    . 1986. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. USA 83: 7089–7093.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Koenig, S.,
    2. H. E. Gendelman,
    3. J. M. Orenstein,
    4. M. C. Dal Canto,
    5. G. H. Pezeshkpour,
    6. M. Yungbluth,
    7. F. Janotta,
    8. A. Aksamit,
    9. M. A. Martin,
    10. A. S. Fauci
    . 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089–1093.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Wu, D. T.,
    2. S. E. Woodman,
    3. J. M. Weiss,
    4. C. M. McManus,
    5. T. G. D’Aversa,
    6. J. Hesselgesser,
    7. E. O. Major,
    8. A. Nath,
    9. J. W. Berman
    . 2000. Mechanisms of leukocyte trafficking into the CNS. J. Neurovirol. 6(Suppl. 1): S82–S85.
    OpenUrlPubMed
  10. ↵
    1. Eugenin, E. A.,
    2. J. W. Berman
    . 2007. Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J. Neurosci. 27: 12844–12850.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Yadav, A.,
    2. R. G. Collman
    . 2009. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 4: 430–447.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Nath, A.,
    2. K. Conant,
    3. P. Chen,
    4. C. Scott,
    5. E. O. Major
    . 1999. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J. Biol. Chem. 274: 17098–17102.
    OpenUrlAbstract/FREE Full Text
    1. Pulliam, L.,
    2. J. A. Clarke,
    3. M. S. McGrath,
    4. D. Moore,
    5. D. McGuire
    . 1996. Monokine products as predictors of AIDS dementia. AIDS 10: 1495–1500.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tyor, W. R.,
    2. J. D. Glass,
    3. J. W. Griffin,
    4. P. S. Becker,
    5. J. C. McArthur,
    6. L. Bezman,
    7. D. E. Griffin
    . 1992. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann. Neurol. 31: 349–360.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Cinque, P.,
    2. L. Vago,
    3. M. Mengozzi,
    4. V. Torri,
    5. D. Ceresa,
    6. E. Vicenzi,
    7. P. Transidico,
    8. A. Vagani,
    9. S. Sozzani,
    10. A. Mantovani, et al
    . 1998. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12: 1327–1332.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kelder, W.,
    2. J. C. McArthur,
    3. T. Nance-Sproson,
    4. D. McClernon,
    5. D. E. Griffin
    . 1998. β-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 44: 831–835.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Yuan, L.,
    2. L. Qiao,
    3. F. Wei,
    4. J. Yin,
    5. L. Liu,
    6. Y. Ji,
    7. D. Smith,
    8. N. Li,
    9. D. Chen
    . 2013. Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J. Neurovirol. 19: 144–149.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Brabers, N. A.,
    2. H. S. Nottet
    . 2006. Role of the pro-inflammatory cytokines TNF-α and IL-1β in HIV-associated dementia. Eur. J. Clin. Invest. 36: 447–458.
    OpenUrlCrossRefPubMed
    1. Genis, P.,
    2. M. Jett,
    3. E. W. Bernton,
    4. T. Boyle,
    5. H. A. Gelbard,
    6. K. Dzenko,
    7. R. W. Keane,
    8. L. Resnick,
    9. Y. Mizrachi,
    10. D. J. Volsky, et al
    . 1992. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J. Exp. Med. 176: 1703–1718.
    OpenUrlAbstract
  20. ↵
    1. Nottet, H. S.,
    2. M. Jett,
    3. C. R. Flanagan,
    4. Q.-H. Zhai,
    5. Y. Persidsky,
    6. A. Rizzino,
    7. E. W. Bernton,
    8. P. Genis,
    9. T. Baldwin,
    10. J. Schwartz, et al
    . 1995. A regulatory role for astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-alpha by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J. Immunol. 154: 3567–3581.
    OpenUrlAbstract
  21. ↵
    1. Talley, A. K.,
    2. S. Dewhurst,
    3. S. W. Perry,
    4. S. C. Dollard,
    5. S. Gummuluru,
    6. S. M. Fine,
    7. D. New,
    8. L. G. Epstein,
    9. H. E. Gendelman,
    10. H. A. Gelbard
    . 1995. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol. Cell. Biol. 15: 2359–2366.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Esiri, M. M.,
    2. J. Carter,
    3. J. W. Ironside
    . 2000. Prion protein immunoreactivity in brain samples from an unselected autopsy population: findings in 200 consecutive cases. Neuropathol. Appl. Neurobiol. 26: 273–284.
    OpenUrlCrossRefPubMed
    1. McLennan, N. F.,
    2. K. A. Rennison,
    3. J. E. Bell,
    4. J. W. Ironside
    . 2001. In situ hybridization analysis of PrP mRNA in human CNS tissues. Neuropathol. Appl. Neurobiol. 27: 373–383.
    OpenUrlCrossRefPubMed
    1. Dürig, J.,
    2. A. Giese,
    3. W. Schulz-Schaeffer,
    4. C. Rosenthal,
    5. U. Schmücker,
    6. J. Bieschke,
    7. U. Dührsen,
    8. H. A. Kretzschmar
    . 2000. Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br. J. Haematol. 108: 488–495.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Deli, M. A.,
    2. S. Sakaguchi,
    3. R. Nakaoke,
    4. C. S. Abrahám,
    5. H. Takahata,
    6. J. Kopacek,
    7. K. Shigematsu,
    8. S. Katamine,
    9. M. Niwa
    . 2000. PrP fragment 106-126 is toxic to cerebral endothelial cells expressing PrP(C). Neuroreport 11: 3931–3936.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Stahl, N.,
    2. D. R. Borchelt,
    3. K. Hsiao,
    4. S. B. Prusiner
    . 1987. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51: 229–240.
    OpenUrlCrossRefPubMed
    1. Vincent, B.,
    2. E. Paitel,
    3. P. Saftig,
    4. Y. Frobert,
    5. D. Hartmann,
    6. B. De Strooper,
    7. J. Grassi,
    8. E. Lopez-Perez,
    9. F. Checler
    . 2001. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J. Biol. Chem. 276: 37743–37746.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Altmeppen, H. C.,
    2. J. Prox,
    3. B. Puig,
    4. M. A. Kluth,
    5. C. Bernreuther,
    6. D. Thurm,
    7. E. Jorissen,
    8. B. Petrowitz,
    9. U. Bartsch,
    10. B. De Strooper, et al
    . 2011. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Mol. Neurodegener. 6: 36.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Viegas, P.,
    2. N. Chaverot,
    3. H. Enslen,
    4. N. Perrière,
    5. P.-O. Couraud,
    6. S. Cazaubon
    . 2006. Junctional expression of the prion protein PrPC by brain endothelial cells: a role in trans-endothelial migration of human monocytes. J. Cell Sci. 119: 4634–4643.
    OpenUrlAbstract/FREE Full Text
    1. de Almeida, C. J.,
    2. L. B. Chiarini,
    3. J. P. da Silva,
    4. P. M. E Silva,
    5. M. A. Martins,
    6. R. Linden
    . 2005. The cellular prion protein modulates phagocytosis and inflammatory response. J. Leukoc. Biol. 77: 238–246.
    OpenUrlAbstract/FREE Full Text
    1. Bainbridge, J.,
    2. K. B. Walker
    . 2005. The normal cellular form of prion protein modulates T cell responses. Immunol. Lett. 96: 147–150.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Brown, D. R.,
    2. C. M. Mohn
    . 1999. Astrocytic glutamate uptake and prion protein expression. Glia 25: 282–292.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Roberts, T. K.,
    2. E. A. Eugenin,
    3. S. Morgello,
    4. J. E. Clements,
    5. M. C. Zink,
    6. J. W. Berman
    . 2010. PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation. Am. J. Pathol. 177: 1848–1860.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Jeon, J.-W.,
    2. B.-C. Park,
    3. J.-G. Jung,
    4. Y.-S. Jang,
    5. E.-C. Shin,
    6. Y. W. Park
    . 2013. The soluble form of the cellular prion protein enhances phagocytic activity and cytokine production by human monocytes via activation of ERK and NF-κB. Immune Netw. 13: 148–156.
    OpenUrl
  35. ↵
    1. Bass, N. H.,
    2. H. H. Hess,
    3. A. Pope,
    4. C. Thalheimer
    . 1971. Quantitative cytoarchitectonic distribution of neurons, glia, and DNa in rat cerebral cortex. J. Comp. Neurol. 143: 481–490.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Nedergaard, M.,
    2. B. Ransom,
    3. S. A. Goldman
    . 2003. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 26: 523–530.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Takeda, S.
    2009. Three-dimensional domain architecture of the ADAM family proteinases. Semin. Cell Dev. Biol. 20: 146–152.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Fahrenholz, F.,
    2. S. Gilbert,
    3. E. Kojro,
    4. S. Lammich,
    5. R. Postina
    . 2000. α-Secretase activity of the disintegrin metalloprotease ADAM 10. Influences of domain structure. Ann. N. Y. Acad. Sci. 920: 215–222.
    OpenUrlPubMed
    1. Reiss, K.,
    2. T. Maretzky,
    3. A. Ludwig,
    4. T. Tousseyn,
    5. B. de Strooper,
    6. D. Hartmann,
    7. P. Saftig
    . 2005. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and β-catenin nuclear signalling. EMBO J. 24: 742–752.
    OpenUrlAbstract/FREE Full Text
    1. Lammich, S.,
    2. E. Kojro,
    3. R. Postina,
    4. S. Gilbert,
    5. R. Pfeiffer,
    6. M. Jasionowski,
    7. C. Haass,
    8. F. Fahrenholz
    . 1999. Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA 96: 3922–3927.
    OpenUrlAbstract/FREE Full Text
    1. Hartmann, D.,
    2. B. de Strooper,
    3. L. Serneels,
    4. K. Craessaerts,
    5. A. Herreman,
    6. W. Annaert,
    7. L. Umans,
    8. T. Lübke,
    9. A. Lena Illert,
    10. K. von Figura,
    11. P. Saftig
    . 2002. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for α-secretase activity in fibroblasts. Hum. Mol. Genet. 11: 2615–2624.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Hundhausen, C.,
    2. D. Misztela,
    3. T. A. Berkhout,
    4. N. Broadway,
    5. P. Saftig,
    6. K. Reiss,
    7. D. Hartmann,
    8. F. Fahrenholz,
    9. R. Postina,
    10. V. Matthews, et al
    . 2003. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186–1195.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Eugenin, E. A.,
    2. J. W. Berman
    . 2003. Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 29: 351–361.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Hoettecke, N.,
    2. A. Ludwig,
    3. S. Foro,
    4. B. Schmidt
    . 2010. Improved synthesis of ADAM10 inhibitor GI254023X. Neurodegener. Dis. 7: 232–238.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Williams, D. W.,
    2. E. A. Eugenin,
    3. T. M. Calderon,
    4. J. W. Berman
    . 2012. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J. Leukoc. Biol. 91: 401–415.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Coley, J. S.,
    2. T. M. Calderon,
    3. P. J. Gaskill,
    4. E. A. Eugenin,
    5. J. W. Berman
    . 2015. Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. PLoS One 10: e0117450.
    OpenUrl
  47. ↵
    1. Brack-Werner, R.
    1999. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 13: 1–22.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Lima, F. R.,
    2. C. P. Arantes,
    3. A. G. Muras,
    4. R. Nomizo,
    5. R. R. Brentani,
    6. V. R. Martins
    . 2007. Cellular prion protein expression in astrocytes modulates neuronal survival and differentiation. J. Neurochem. 103: 2164–2176.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Nolting, T.,
    2. A. Lindecke,
    3. E. Koutsilieri,
    4. M. Maschke,
    5. I.-W. Husstedt,
    6. S. Sopper,
    7. O. Stüve,
    8. H.-P. Hartung,
    9. G. Arendt, Competence Network HIV/AIDS
    . 2009. Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array. J. Neurovirol. 15: 390–400.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Taylor, D. R.,
    2. E. T. Parkin,
    3. S. L. Cocklin,
    4. J. R. Ault,
    5. A. E. Ashcroft,
    6. A. J. Turner,
    7. N. M. Hooper
    . 2009. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J. Biol. Chem. 284: 22590–22600.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Letendre, S. L.,
    2. J. C. Zheng,
    3. M. Kaul,
    4. C. T. Yiannoutsos,
    5. R. J. Ellis,
    6. M. J. Taylor,
    7. J. Marquie-Beck,
    8. B. Navia, HIV Neuroimaging Consortium
    . 2011. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J. Neurovirol. 17: 63–69.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Gerszten, R. E.,
    2. E. A. Garcia-Zepeda,
    3. Y.-C. Lim,
    4. M. Yoshida,
    5. H. A. Ding,
    6. M. A. Gimbrone Jr..,
    7. A. D. Luster,
    8. F. W. Luscinskas,
    9. A. Rosenzweig
    . 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398: 718–723.
    OpenUrlCrossRefPubMed
  53. ↵
    1. McLennan, H.
    1976. The autoradiographic localization of L-[3h]glutamate in rat brain tissue. Brain Res. 115: 139–144.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Bondy, S. C.,
    2. D. K. Lee
    . 1993. Oxidative stress induced by glutamate receptor agonists. Brain Res. 610: 229–233.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Málaga-Trillo, E.,
    2. G. P. Solis,
    3. Y. Schrock,
    4. C. Geiss,
    5. L. Luncz,
    6. V. Thomanetz,
    7. C. A. Stuermer
    . 2009. Regulation of embryonic cell adhesion by the prion protein. PLoS Biol. 7: e55.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Anders, A.,
    2. S. Gilbert,
    3. W. Garten,
    4. R. Postina,
    5. F. Fahrenholz
    . 2001. Regulation of the α-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 15: 1837–1839.
    OpenUrlFREE Full Text
  57. ↵
    1. Qiu, H.,
    2. X. Tang,
    3. J. Ma,
    4. K. Shaverdashvili,
    5. K. Zhang,
    6. B. Bedogni
    . 2015. Notch1 autoactivation via transcriptional regulation of furin, which sustains Notch1 signaling by processing Notch1-activating proteases ADAM10 and membrane type 1 matrix metalloproteinase. Mol. Cell. Biol. 35: 3622–3632.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Kopan, R.,
    2. M. X. G. Ilagan
    . 2009. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216–233.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Kageyama, R.,
    2. T. Ohtsuka
    . 1999. The Notch-Hes pathway in mammalian neural development. Cell Res. 9: 179–188.
    OpenUrlCrossRefPubMed
    1. Belyea, B. C.,
    2. S. Naini,
    3. R. C. Bentley,
    4. C. M. Linardic
    . 2011. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin. Cancer Res. 17: 7324–7336.
    OpenUrlAbstract/FREE Full Text
    1. Fischer, A.,
    2. N. Schumacher,
    3. M. Maier,
    4. M. Sendtner,
    5. M. Gessler
    . 2004. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 18: 901–911.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Dos Santos Schiavinato, J. L.,
    2. L. H. B. Oliveira,
    3. A. G. Araujo,
    4. M. D. Orellana,
    5. P. V. B. de Palma,
    6. D. T. Covas,
    7. M. A. Zago,
    8. R. A. Panepucci
    . 2016. TNF-alpha and Notch signaling regulates the expression of HOXB4 and GATA3 during early T lymphopoiesis. In Vitro Cell. Dev. Biol. Anim. 52: 920–934.
    OpenUrl
    1. Ando, K.,
    2. S. Kanazawa,
    3. T. Tetsuka,
    4. S. Ohta,
    5. X. Jiang,
    6. T. Tada,
    7. M. Kobayashi,
    8. N. Matsui,
    9. T. Okamoto
    . 2003. Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts. Oncogene 22: 7796–7803.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Wang, H.,
    2. Y. Tian,
    3. J. Wang,
    4. K. L. Phillips,
    5. A. L. Binch,
    6. S. Dunn,
    7. A. Cross,
    8. N. Chiverton,
    9. Z. Zheng,
    10. I. M. Shapiro, et al
    . 2013. Inflammatory cytokines induce NOTCH signaling in nucleus pulposus cells: implications in intervertebral disc degeneration. J. Biol. Chem. 288: 16761–16774.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Srour, N.,
    2. A. Lebel,
    3. S. McMahon,
    4. I. Fournier,
    5. M. Fugère,
    6. R. Day,
    7. C. M. Dubois
    . 2003. TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett. 554: 275–283.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Cissé, M. A.,
    2. C. Sunyach,
    3. S. Lefranc-Jullien,
    4. R. Postina,
    5. B. Vincent,
    6. F. Checler
    . 2005. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J. Biol. Chem. 280: 40624–40631.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Moss, M. L.,
    2. G. Powell,
    3. M. A. Miller,
    4. L. Edwards,
    5. B. Qi,
    6. Q.-X. A. Sang,
    7. B. De Strooper,
    8. I. Tesseur,
    9. S. F. Lichtenthaler,
    10. M. Taverna, et al
    . 2011. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. J. Biol. Chem. 286: 40443–40451.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Carnini, A.,
    2. S. Casha,
    3. V. W. Yong,
    4. R. J. Hurlbert,
    5. J. E. Braun
    . 2010. Reduction of PrP(C) in human cerebrospinal fluid after spinal cord injury. Prion 4: 80–86.
    OpenUrlPubMed
  69. ↵
    1. Santuccione, A.,
    2. V. Sytnyk,
    3. I. Leshchyns’ka,
    4. M. Schachner
    . 2005. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J. Cell Biol. 169: 341–354.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Krebs, B.,
    2. C. Dorner-Ciossek,
    3. R. Schmalzbauer,
    4. N. Vassallo,
    5. J. Herms,
    6. H. A. Kretzschmar
    . 2006. Prion protein induced signaling cascades in monocytes. Biochem. Biophys. Res. Commun. 340: 13–22.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Gauczynski, S.,
    2. J. M. Peyrin,
    3. S. Haïk,
    4. C. Leucht,
    5. C. Hundt,
    6. R. Rieger,
    7. S. Krasemann,
    8. J. P. Deslys,
    9. D. Dormont,
    10. C. I. Lasmézas,
    11. S. Weiss
    . 2001. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J. 20: 5863–5875.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Anderson, C. M.,
    2. R. A. Swanson
    . 2000. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32: 1–14.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Selvaggini, C.,
    2. L. De Gioia,
    3. L. Cantù,
    4. E. Ghibaudi,
    5. L. Diomede,
    6. F. Passerini,
    7. G. Forloni,
    8. O. Bugiani,
    9. F. Tagliavini,
    10. M. Salmona
    . 1993. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem. Biophys. Res. Commun. 194: 1380–1386.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Forloni, G.,
    2. N. Angeretti,
    3. R. Chiesa,
    4. E. Monzani,
    5. M. Salmona,
    6. O. Bugiani,
    7. F. Tagliavini
    . 1993. Neurotoxicity of a prion protein fragment. Nature 362: 543–546.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Gimbel, D. A.,
    2. H. B. Nygaard,
    3. E. E. Coffey,
    4. E. C. Gunther,
    5. J. Laurén,
    6. Z. A. Gimbel,
    7. S. M. Strittmatter
    . 2010. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30: 6367–6374.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Laurén, J.,
    2. D. A. Gimbel,
    3. H. B. Nygaard,
    4. J. W. Gilbert,
    5. S. M. Strittmatter
    . 2009. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128–1132.
    OpenUrlCrossRefPubMed
    1. Nygaard, H. B.,
    2. S. M. Strittmatter
    . 2009. Cellular prion protein mediates the toxicity of β-amyloid oligomers: implications for Alzheimer disease. Arch. Neurol. 66: 1325–1328.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Kellett, K. A.,
    2. N. M. Hooper
    . 2009. Prion protein and Alzheimer disease. Prion 3: 190–194.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Rezaie, P.,
    2. C. C. Pontikis,
    3. L. Hudson,
    4. N. J. Cairns,
    5. P. L. Lantos
    . 2005. Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer’s disease, diffuse Lewy body disease, and in normal brain: an immunohistochemical study. J. Histochem. Cytochem. 53: 929–940.
    OpenUrlCrossRefPubMed
  80. ↵
    1. Voigtländer, T.,
    2. S. Klöppel,
    3. P. Birner,
    4. C. Jarius,
    5. H. Flicker,
    6. S. Verghese-Nikolakaki,
    7. T. Sklaviadis,
    8. M. Guentchev,
    9. H. Budka
    . 2001. Marked increase of neuronal prion protein immunoreactivity in Alzheimer’s disease and human prion diseases. Acta Neuropathol. 101: 417–423.
    OpenUrlPubMed
  81. ↵
    1. Nieznanski, K.,
    2. J.-K. Choi,
    3. S. Chen,
    4. K. Surewicz,
    5. W. K. Surewicz
    . 2012. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. J. Biol. Chem. 287: 33104–33108.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Meyne, F.,
    2. S. F. Gloeckner,
    3. B. Ciesielczyk,
    4. U. Heinemann,
    5. A. Krasnianski,
    6. B. Meissner,
    7. I. Zerr
    . 2009. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J. Alzheimers Dis. 17: 863–873.
    OpenUrlPubMed
  83. ↵
    1. Maretzky, T.,
    2. F. Scholz,
    3. B. Köten,
    4. E. Proksch,
    5. P. Saftig,
    6. K. Reiss
    . 2008. ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis. J. Invest. Dermatol. 128: 1737–1746.
    OpenUrlCrossRefPubMed
    1. Gatta, L. B.,
    2. A. Albertini,
    3. R. Ravid,
    4. D. Finazzi
    . 2002. Levels of β-secretase BACE and α-secretase ADAM10 mRNAs in Alzheimer hippocampus. Neuroreport 13: 2031–2033.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Wu, E.,
    2. P. I. Croucher,
    3. N. McKie
    . 1997. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem. Biophys. Res. Commun. 235: 437–442.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Saftig, P.,
    2. K. Reiss
    . 2011. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur. J. Cell Biol. 90: 527–535.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Murumkar, P. R.,
    2. S. DasGupta,
    3. S. R. Chandani,
    4. R. Giridhar,
    5. M. R. Yadav
    . 2010. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin. Ther. Pat. 20: 31–57.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section